Skip to main content

Oncolytics Biotech Value Stock - Dividend - Research Selection

Oncolytics biotech

ISIN: CA6823108759 , WKN: A2JMW5

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Oncolytics Biotech shares are trading higher after Form 4 filings showed several members of its Board of Directors have made purchases of the stock.

2026-02-13

12 Health Care Stocks Moving In Friday's Intraday Session

2026-02-13

Oncolytics Biotech Says FDA Grants Fast Track Designation To Pelareorep In Combination With Bevacizumab And Leucovorin, FOLFIRI For Treatment Of Patients With KRAS-Mutant, MSS mCRC In 2L Setting

2026-02-04
Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat populationCompany to launch controlled study in second-line KRAS-mutant MSS mCRC with interim

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

2026-02-04

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

2026-01-15
All resolutions passed, enabling the Company to streamline regulatory and operational processesSAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Special Meeting of Shareholders (the “Special Meeting”) held on Thursday, January 15, 2026. Each item of business described in the management information circular/prospectus of the

Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript

2026-01-15
Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call January 15, 2026 10:00 AM ESTCompany ParticipantsKirk Look - Chief Financial OfficerAllison Hagerman...

Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

2026-01-14
Appointments strengthen late-stage clinical execution and statistical leadership as the Company advances multiple registration-directed programs in gastrointestinal cancersSAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biost

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

2026-01-12
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no approved therapy SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced updated clinical data from GOBLET Cohort 4 in patients with third-line metastatic squamous c

Oncolytics Biotech Announces Updated Clinical Data From GOBLET Cohort 4 In Third-Line Metastatic SCAC; Says Compared To Historical Benchmark, Nearly Tripled ORR

2026-01-12

Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances

2026-01-12
Oncolytics Biotech Inc. (NASDAQ:ONCY) is included in our list of the stocks under $1 that will explode. Oncolytics Biotech Inc. (NASDAQ:ONCY) shared a leadership update on January 7, 2026. With the appointment of Dr. Eileen O’Reilly of Memorial Sloan Kettering Cancer Center, Dr. Neil Segal of MSK, and Dr. Van Morris of MD Anderson Cancer […]